Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation
of plasma cells. Although therapeutic advances have been made to improve clinical …

In a short time, single-cell platforms have become the norm in many fields of research,
including multiple myeloma (MM). In fact, the large amount of cellular heterogeneity in MM …

Markers that predict response and resistance to chimeric antigen receptor (CAR) T cells in
relapsed/refractory multiple myeloma are currently missing. We subjected mononuclear cells …

Multiple Myeloma is an incurable plasma cell malignancy with a poor survival rate that is
usually treated with immunomodulatory drugs (iMiDs) and proteosome inhibitors (PIs). The …

Single-cell RNA sequencing (scRNA-seq) is a widely used technique for characterizing
individual cells and studying gene expression at the single-cell level. Clustering plays a vital …

Gene regulatory network inference (GRNI) is a challenging problem, particularly owing to
the presence of zeros in single-cell RNA sequencing data: some are biological zeros …

Multiple myeloma (MM) growth is supported by an immune-tolerant bone marrow
microenvironment. Here, we find that loss of Never in mitosis gene A (NIMA)-related kinase …

Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance,
and T-cell clones of uncertain significance are three premalignant conditions characterised …

The treatment landscape for multiple myeloma (MM) has experienced substantial progress
over the last decade. Despite the efficacy of new substances, patient responses tend to still …

The bone marrow (BM) microenvironment is critical for dissemination, growth, and survival of
multiple myeloma (MM) cells. Homing of myeloma cells to the BM niche is a crucial step in …